Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Mar-Apr;5(2):49-57.

Pharmaceutical care and health care utilization in an HMO

Affiliations
  • PMID: 11990212
Clinical Trial

Pharmaceutical care and health care utilization in an HMO

Lucy Rose Fischer et al. Eff Clin Pract. 2002 Mar-Apr.

Abstract

Context: The belief that expanding the role of pharmacists in patient care could improve the safety and efficacy of drug therapy is growing. Specifically, pharmaceutical care programs through which pharmacists provide direct and ongoing counseling to patients have been introduced. Whether such programs reduce medication-related problems or health care utilization is unknown.

Objective: To assess whether a pharmaceutical care program decreases health care utilization, medication use, or charges.

Design: Nonrandomized, controlled trial.

Setting: Staff clinic and freestanding contract pharmacies affiliated with a large HMO in greater Minneapolis-St. Paul (6 intervention pharmacies, 143 control pharmacies).

Study population: Adult HMO enrollees (n = 921) with heart or lung disease who used one of the selected pharmacies.

Intervention: Patients at intervention pharmacies were invited to participate in the pharmaceutical care program. The protocol-based program consisted of scheduled meetings between trained pharmacists and patients to assess drug therapy, plan goals, and intervene through counseling and/or consultation with other health professionals.

Outcome measures: Change in number of outpatient clinic visits, unique medications dispensed, and total charges over 1 year of follow-up.

Results: In an intention-to-treat analysis (after adjustment for gender, age, Charlson Comorbidity Index, disease category, and the baseline value of the utilization measure), the number of unique medications for patients in the pharmaceutical care group increased more than in the usual care group (1.0 vs. 0.4 unique medications; P = 0.03). There was no difference between the two groups in the change in total number of clinic visits or total costs. In secondary adherence analyses, participants were more likely than the usual care group to increase the number of clinic visits (1.2 vs. -0.9; P = < 0.01) and number of unique medications (1.0 vs. 0.2; P = 0.02).

Conclusion: Pharmaceutical care for patients with chronic health conditions appears to be associated with a modest increase rather than a decrease in health care utilization.

PubMed Disclaimer

Comment in

Publication types